Streetbeat News

Price Targets

LSTA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:11 pm

NUWE

Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Nuwellis (NASDAQ:NUWE) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:08 pm

CALC

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on CalciMedica (NASDAQ:CALC) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:05 pm

BIOR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:04 pm

AIG

Analysts' ratings for American International Group (NYSE:AIG) over the last quarter show a range of sentiments from bullish to bearish. The average 12-month price target is $84.0, slightly down from the previous $84.62. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting mixed views on AIG's future performance. Key financial indicators show challenges in revenue growth, net margin, ROE, and ROA, but a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 6:02 pm

ADAP

HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ:ADAP) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:02 pm

TGLS

Four analysts have recently evaluated Tecnoglass (NYSE:TGLS), showing a range of sentiments from bullish to indifferent. The average 12-month price target has increased by 14.7% to $65.0. Analysts have raised their ratings and price targets, reflecting a positive outlook despite some revenue challenges.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 6:01 pm

ALNT

Analysts' ratings for Allient (NASDAQ:ALNT) have varied from bullish to bearish over the last quarter. The average 12-month price target has dropped by 19.11% to $31.75. Recent actions by analysts include lowering ratings and price targets, reflecting dynamic market conditions and company performance. Allient's financial health shows challenges in revenue growth but strong net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 6:01 pm

AKAM

Akamai Technologies (NASDAQ:AKAM) has received a range of analyst ratings over the past quarter, with a majority being bullish. The average 12-month price target has increased to $115.2, reflecting a positive sentiment shift. Analysts have raised their price targets and ratings, indicating confidence in Akamai's market performance and financial health.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 6:01 pm

MREO

Needham analyst Gil Blum has reiterated a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:58 pm